Inorganic matrices: an answer to low drug solubility problem

References

• Thomas VH, Bhattachar S, Hitchingham L, The road map to oral bioavailability: an industrial perspective. Expert Opin Drug Metab Toxicol 2006;2:591-608
   PubMed Web of Science ®Google Scholar
• Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods 2000;44:235-49
   PubMed Web of Science ®Google Scholar
• Kerns EH, Di L. Drug-like properties: concept, structure design and methods. Academic Press; London: 2008. p. 56-67
   Google Scholar
• Benet LZ. Predicting DMPK of NMEs: what do we need in terms of science and tools? New England drug metabolism discussion group: Gerald Miwa Retirement Symposium; 2007
   Google Scholar
• Ruddy SB, Callanan F. The insoluble solved. Drug Discov Dev 2011;14:24-5
   Google Scholar
• Babu NJ, Nangia A. Solubility advantage of amorphous drugs and pharmaceutical cocrystals. Cryst Growth Des 2011;11:2662-79
   Web of Science ®Google Scholar
• Bhattachar SN, Deschenes LA, Wesley JA. Solubility: it's not just for physical chemists. Drug Discov Today 2006;11:1012-18
   PubMed Web of Science ®Google Scholar
• Hörter D, Dressman JB. Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. Adv Drug Deliv Rev 2001;46:75-87
   PubMed Web of Science ®Google Scholar
• Levich VG. Physicochemical hydrodynamics. Prentice-Hall; Englewood Cliffs, N.J: 1962
   Google Scholar
• Dokoumetzidis A, Macheras P. A century of dissolution research: from Noyes and Whitney to the Biopharmaceutics Classification System. Int J Pharm 2006;321:1-11
   PubMed Web of Science ®Google Scholar
• Mudie DM, Amidon GL, Amidon GE. Physiological parameters for oral delivery and in vitro testing. Mol Pharm 2010;7:1388-405
   PubMed Web of Science ®Google Scholar
• Sugano K, Okazaki A, Sugimoto S, Solubility and dissolution profile assessment in drug discovery. Drug Metab Pharmacokinet 2007;22:225-54
   PubMed Web of Science ®Google Scholar
• Singhal D, Curatolo W. Drug polymorphism and dosage form design: a pratical perspective. Adv Drug Deliv Rev 2004;56:335-47
   PubMed Web of Science ®Google Scholar
• Puri V, Dantuluri AK, Kumar M, Wettability and surface chemistry of crystalline and amorphous forms of a poorly water soluble drug. Eur J Pharm Sci 2010;40:84-93
   PubMed Web of Science ®Google Scholar
• Dressman JB, Amidon GL, Reppas C, Dissolution testing as prognostic tool for oral drug absorption: immediate release dosage forms. Pharm Res 1998;15:11-22
   PubMed Web of Science ®Google Scholar
• Abrahamsson B, Albery T, Eriksson A, Food effects on tablet disintegration. Eur J Pharm Sci 2004;22:165-72
   PubMed Web of Science ®Google Scholar
• Fleisher D, Li C, Zhou Y, Drug, meal and formulation interactions influencing drug absorption after oral administration. Clin Pharmacokinet 1999;36:233-54
   PubMed Web of Science ®Google Scholar
• Mosharraf M, Nyström C. The effect of particle size and shape on the surface specific dissolution rate of microsized practically insoluble drugs. Int J Pharm 1995;122:35-47
   Web of Science ®Google Scholar
• Aleeva GN, Zhuravleva MV, Khafizyanova RK. The role of excipients in determining the pharmaceutical and therapeutic properties of medicinal agents. Pharm Chem J 2009;43:230-4
   Web of Science ®Google Scholar
• Amidon GL, Lennernäs H, Shah VP, A Theoretical basis for a biopharmaceutics drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995;12:413-19
   PubMed Web of Science ®Google Scholar
• Lindenberg M, Kopp S, Dressman JB. Classification of orally administered drugs on the World Health Organization model list of the essential medicines according to the biopharmaceutics classification system. Eur J Pharm Biopharm 2004;58:265-78
   PubMed Web of Science ®Google Scholar
• Varma MVS, Khandavilli S, Ashokraj Y, Biopharmaceutic Classification System: a scientific framework for pharmacokinetic optimization in drug research. Curr Drug Metab 2004;5:375-88
   PubMed Web of Science ®Google Scholar
• Rinaki E, Valsami G, Macheras P. Quantitative biopharmaceutics classification system: the central role of dose/solubility ratio. Pharm Res 2003;20:1917-25
   PubMed Web of Science ®Google Scholar
• Gomez-Orellana I. Strategies to improve oral drug bioavailability. Expert Opin On Drug Deliv 2005;2:419-33
   PubMed Web of Science ®Google Scholar
• Coceani N, Magarotto L, Ceschia D, Theoretical and experimental analysis of drug release from an ensemble of polymeric particles containing amorphous and nano-crystalline drug. Chem Eng Sci 2012;71:345-55
   Web of Science ®Google Scholar
• Cho E, Cho W, Ho Cha K, Enhanced dissolution of megestrol acetate microcrystals prepared by antisolvent precipitation process using hydrophilic additives. Intl J Pharm 2010;396(1-2):91-8
   PubMed Web of Science ®Google Scholar
• Junghanns JAH, Müller RH. Nanocrystal technology, drug delivery and clinical applications. Int J Nanomedicine 2008;3:295-309
   PubMed Web of Science ®Google Scholar
• Murdande SB, Pikal MJ, Shanker RM. Solubility advantage of amorphous pharmaceuticals: I. A thermodynamic analysis. J Pharm Sci 2010;99:1254-64
   PubMed Web of Science ®Google Scholar
• Vasconcelos T, Sarmento B, Costa P. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug Discov Today 2007;12:1068-75
   PubMed Web of Science ®Google Scholar
• Yoshida T, Kurimoto I, Yoshihara K, Aminoalkyl methacrylate copolymers for improving the solubility of tacrolimus. I: evaluation of solid dispersion formulations. Int J Pharm 2012;428(1-2):18-24
   PubMedGoogle Scholar
• Bahl D, Bogner RH. Amorphization of indomethacin by co-grinding with Neusilin US2: amorphization kinetics, physical stability and mechanism. Pharm Res 2006;23:2317-25
   PubMed Web of Science ®Google Scholar
• Colombo I, G, Grassi M, Grassi Drug mechanochemical activation. 2009;98:3961-86
   Google Scholar
• Kurkov SV, Loftsson T. Cyclodextrins. Int J Pharm 2012; Available from: http://dx.doi.org/10.1016/j.ijpharm.2012.06.055
   PubMedGoogle Scholar
• Hauss DJ. Oral lipid-based formulations. Adv Drug Deliv Rev 2007;59:667-76
   PubMed Web of Science ®Google Scholar
• Kohli K, Chopra S, Dhar D, Self-emulsifying drug delivery systems: an approach to enhance oral bioavailability. Drug Discov Today 2010;15:958-65
   PubMed Web of Science ®Google Scholar
• Müller RH, Runge S, Ravelli V, Oral bioavailability of cyclosporine: Solid lipid nanoparticles (SLN®) versus drug nanocrystals. Int J Pharm 2006;317:82-9
   PubMed Web of Science ®Google Scholar
• Porter CJH, Trevaskis NL, Charman WN. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov 2007;6:231-48
   PubMed Web of Science ®Google Scholar
• Heikkilä T, Salonen J, Tuura J, Evaluation of mesoporous TCPSi, MCM-41, SBA-15, and TUD-1 materials as API carriers for oral drug delivery. Drug Deliv 2007;14:337-47
   PubMed Web of Science ®Google Scholar
• Del Hoyo C. Layered double hydroxides and human health: an overview. Appl Clay Sci 2007;36:103-21
   Web of Science ®Google Scholar
• Choy JH, Choi SJ, Oh JM, Clay minerals and layered double hydroxides for novel biological applications. Appl Clay Sci 2007;36:122-32
   Web of Science ®Google Scholar
• Tammaro L, Costantino U, Bolognese A, Nanohybrids for controlled antibiotic release in topical applications. Int J Antimicrob Agents 2007;29:417-23
   PubMed Web of Science ®Google Scholar
• Van Speybroeck M, Barillaro V, Thi TD, Ordered mesoporous silica material SBA-15: a broad-spectrum formulation platform for poorly soluble drugs. J Pharm Sci 2009;98:2648-58
   PubMed Web of Science ®Google Scholar
• Ambrogi V, Perioli L, Marmottini F, Improvement of dissolution rate of piroxicam by inclusion into MCM-41 mesoporous silicate. Eur J Pharm Sci 2007;32:216-22
   PubMed Web of Science ®Google Scholar
• Sing SK, Everett DH, Haul AW, Reporting physisorption data for gas/solid systems with special reference to the determination of surface area and porosity. Pure Appl Chem 1985;57:603-19
   Web of Science ®Google Scholar
• Manzano M, Colilla M, Vallet-Regì M. Drug delivery from ordered mesoporous matricers. Exp Opin 2009;6:1383-400
   Web of Science ®Google Scholar
• Meynen V, Cool P, Vansant EF. Verified syntheses of mesoporous materials. Micropor Mesopor Mater 2009;125:170-223
   Web of Science ®Google Scholar
• Kresge CT, Leonowicz ME, Roth WJ, Ordered mesoporous molecular sieves synthesized by a liquid crystal template mechanism. Nature 1992;359:710-12
   Web of Science ®Google Scholar
• Brühwiler D, Calzaferri G. Molecular sieves as host materials for supramolecular organization. Micropor Mesopor Mater 2004;72:1-23
   Web of Science ®Google Scholar
• Wang S. Ordered mesoporous materials for drug delivery. Micropor Mesopor Mater 2009;117:1-9
   Web of Science ®Google Scholar
• Ciesla U, Schüth F. Ordered mesoporous materials. Micropor Mesopor Mater 1999;27:131-49
   Web of Science ®Google Scholar
• Beck JS, Vartuli JC, Roth WJ, A new family of mesoporous molecular sieves prepared with liquid crystal templates. J Am Chem Soc 1992;114:10834-43
   Web of Science ®Google Scholar
• Zhao D, Feng J, Huo Q, Triblock copolymer syntheses of mesoporous silica with periodic 50 to 300 angstrom pores. Science 1998;279:548-52
   PubMed Web of Science ®Google Scholar
• Zhao D, Feng J, Huo Q, Nonionic triblock and star diblock copolymer and oligomeric surfactant syntheses of highly ordered, hydrotermally stable, mesoporous silica structures. J Am Chem Soc 1998;120:6024-36
   Web of Science ®Google Scholar
• Celera EB, Kruk M, Zuzek Y, Hydrothermal stability of SBA-15 and related ordered mesoporous silicas with plugged pores. Mater Chem 2006;16:2824-33
   Web of Science ®Google Scholar
• Silvestre-Albero A, Jardim EO, Bruijn E, Is there any microporosity in ordered mesoporous silicas? Langmuir 2009;25:939-43
   PubMed Web of Science ®Google Scholar
• Esparza JM, Ojeda ML, Campero A, N2 sorption scanning behavior of SBA-15 porous substrates. Colloids Surf A Physicochem Eng Asp 2004;241:35-45
   Web of Science ®Google Scholar
• Ambrogi V, Perioli L, Marmottini F, Role of mesoporous silicates on carbamazepine dissolution rate enhancement. Micropor Mesopor Mater 2008;113:445-52
   Web of Science ®Google Scholar
• Ambrogi V, Perioli L, Pagano C, MCM-41 for furosemide dissolution improvement. Micropor Mesopor Mater 2012;147:343-9
   Web of Science ®Google Scholar
• Vadia N, Rajput S. Study on formulation variables of methotrexate loaded mesoporous MCM-41 nanoparticles for dissolution enhancement. Eur J Pharm Sci 2012;45:8-18
   PubMed Web of Science ®Google Scholar
• Heikkilä T, Salonen J, Tuura J, Evaluation of mesoporous TCPSi, MCM-41, SBA-15, and TUD-1 materials as API carriers for oral drug delivery. Drug Deliv 2007;14:337-47
   PubMed Web of Science ®Google Scholar
• Sliwinska-Bartkowiak M, Dudziak G, Gras R, Freezing behavior in porous glasses and MCM-41. Coll Surf A Physicochem Eng Aspects 2001;187:523-9
   Web of Science ®Google Scholar
• Trifirò F, Vaccari A. Solid state supramolecular chemistry: two- and three-dimensional inorganic networks. In: Alberti M, Bein T, editors. Comprehensive supramolecular chemistry. Volume 7 Pergamon-Elsevier; Oxford: 1996. p. 1-46
   Google Scholar
• Pucciariello R, Tammaro L, Villani V, New nanohybrids of poly (Ô-caprolactone) and a modified Mg/Al hydrotalcite: mechanical and thermal properties. J Polymer Sci Part B Polymer physics 2007;45:945-54
   Web of Science ®Google Scholar
• Miyata S. Anion-exchange properties of hydrotalcite-like compounds. Clays Clay Miner 1983;31:305-11
   Web of Science ®Google Scholar
• Costantino U, Ambrogi V, Nocchetti M, Hydrotalcite-like compounds: versatile layered hosts of molecular anions with biological activity. Micropor Mesopor Mater 2008;107:149-60
   Web of Science ®Google Scholar
• Nagaoka K, Jentys A, Lercher JA. Methane autothermal reforming with and without ethane over mono- and bimetal catalysts prepared from hydrotalcite precursors. J Catal 2005;229:185-96
   Web of Science ®Google Scholar
• Costantino U, Coletti N, Nocchetti M. Anion exchange of methyl orange into Zn-Al synthetic hydrotalcite and photophysical characterization of the intercalates obtained. Langmuir 1999;15:4454-60
   Web of Science ®Google Scholar
• Mohana D, Pittman CU. Arsenic removal from water/wastewater using adsorbents-A critical review. J Hazard Mater 2007;142:1-53
   PubMed Web of Science ®Google Scholar
• Carretero MI, Pozo M. Clay and non-clay minerals in the pharmaceutical and cosmetic industries Part II. Active ingredients. Appl Clay Sci 2010;47:171-81
   Web of Science ®Google Scholar
• Li Y, Hou WG, Shen S. Rheological behavior of aqueous suspensions containing cationic starch and aluminum magnesium hydrotalcite-like compound in the presence of different electrolytes. Colloids Surf A Physicochem Eng Aspects 2009;350:109-13
   Web of Science ®Google Scholar
• Costantino U, Nocchetti M. Layered double hydroxydes and their intercalation compounds in photochemistry and medicinal chemistry. In: Rives V, editor. Layered double hydroxides: present and future. Nova Science Publishers Inc; New York: 2001. p. 383-411
   Google Scholar
• Aguzzi C, Cerezo P, Viseras C, Use of clays as drug delivery systems: possibilites and limitations. Appl Clay Sci 2007;36:22-36
   Web of Science ®Google Scholar
• Tamura H, Chiba J, Ito M, Synthesis and characterization of hydrotalcite-ATP intercalates. Solid State Ion 2004;172:607-9
   Web of Science ®Google Scholar
• Xu ZP, Lu GQM. Layered double hydroxide nanomaterials as potential cellular drug delivery agents. Pure Appl Chem 2006;78:1771-9
   Web of Science ®Google Scholar
• Ambrogi V, Fardella G, Grandolini G, Intercalation compounds of hydrotalcite-like anionic clays with antiinflammatory agents - I. Intercalation and in vitro release of ibuprofen. Int J Pharm 2001;220:23-32
   PubMed Web of Science ®Google Scholar
• Choy JH, Jung JS, Oh JM, Layered double hydroxide as an efficient drug reservoir for folate derivatives. Biomaterials 2004;25:3059-64
   PubMed Web of Science ®Google Scholar
• Ambrogi V, Perioli L, Ciarnelli V, Effect of gliclazide immobilization into layered double hydroxide on drug release. Eur J Pharm Biopharm 2009;73:285-91
   PubMed Web of Science ®Google Scholar
• Del Arco M, Fernández A, Martín C, Intercalation of mefenamic and meclofenamic acid anions in hydrotalcite-like matrixes. Appl Clay Sci 2007;36:133-40
   Web of Science ®Google Scholar
• Perioli L, Posati T, Nocchetti M, Intercalation and release of antiinflammatory drug diclofenac into nanosized ZnAl hydrotalcite-like compound. Appl Clay Sci 2011;53:374-8
   Web of Science ®Google Scholar
• Ambrogi V, Perioli L, Ricci M, Eudragit® and hydrotalcite-like anionic clay composite system for diclofenac colonic delivery. Micropor Mesopor Mater 2008;115:405-15
   Web of Science ®Google Scholar
• Posati T, Bellezza F, Tarpani L, Selective internalization of ZnAl-HTlc nanoparticles in normal and tumor cells. A study of their potential use in cellular delivery. Appl Clay Sci 2012;55:62-9
   Web of Science ®Google Scholar
• Ambrogi V, Perioli L, Marmottini F, Use of calcined Mg–Al–hydrotalcite to enhance the stability of celecoxib in the amorphous form. Eur J Pharm Biopharm 2007;66:253-9
   PubMed Web of Science ®Google Scholar
• Choi G, Lee JH, Oh YJ, Inorganic-polymer nanohybrid carrier for delivery of a poorly-soluble drug, ursodeoxycholic acid. Int J Pharm 2010;402:117-22
   PubMed Web of Science ®Google Scholar
• Bellezza F, Nocchetti M, Posati T, Synthesis of colloidal dispersions of NiAl, ZnAl, NiCr, ZnCr, NiFe, and MgFe hydrotalcite-like nanoparticles. J Coll Int Sci 2012;376:20-7
   PubMed Web of Science ®Google Scholar
• Rossi C, Schoubben A, Ricci M, Intercalation of the radical scavenger ferulic acid in hydrotalcite-like anionic clays. Int J Pharm 2005;295:47-55
   PubMed Web of Science ®Google Scholar
• Perioli L, Ambrogi V, Bertini B, Anionic clays for sunscreen agent safe use: photoprotection, photostability and prevention of their skin penetration. Eur J Pharm Biopharm 2006;62:185-93
   PubMed Web of Science ®Google Scholar
• Perioli L, Ambrogi V, Rossi C, Use of anionic clays for photoprotection and sunscreen photostability: hydrotalcites and phenylbenzimidazole sulfonic acid. J Phys Chem Sol 2006;67:1079-83
   Web of Science ®Google Scholar
• Perioli L, Nocchetti M, Ambrogi V, Sunscreen immobilization on ZnAl-hydrotalcite for new cosmetic formulations. Micropor Mesopor Mater 2008;107:180-9
   Web of Science ®Google Scholar
• Perioli L, Ambrogi V, Giovagnoli S, Mucoadhesive bilayered tablets for buccal sustained release of flurbiprofen. AAPS PharmSciTech 2007;8(3):E54. Available from: http://www.aapspharmscitech.org
   PubMedGoogle Scholar
• Ambrogi V, Fardella G, Grandolini G, Effect of hydrotalcite like-compounds on the aqueous solubility of some poorly water-soluble drugs. J Pharm Sci 2003;92:1407-18
   PubMed Web of Science ®Google Scholar
• Perioli L, Ambrogi V, di Nauta L, Effects of hydrotalcite-like nanostructured compounds on biopharmaceutical properties and release of BCS class II drugs: the case of flurbiprofen. Appl Clay Sci 2011;51:407-13
   Web of Science ®Google Scholar
• Ambrogi V, Fardella G, Grandolini G, Intercalation compounds of hydrotalcite-like anionic clays with anti-inflammatory agents, II: uptake of diclofenac for a controlled release formulation. AAPS PharmSciTech 2002;2:1-6; article 26
   Google Scholar
• Perioli L, Ambrogi V, Nocchetti M, Preformulation studies on host–guest composites for oral administration of BCS class IV drugs: HTlc and furosemide. Appl Clay Sci 2011;53:696-703
   Web of Science ®Google Scholar
• Gené E, Calvet X, Morón A, Recommendations for the use of anti-inflammatory drugs and indications for gastrointestinal protection in emergency departments. Emergencias 2009;21:295-300
   Web of Science ®Google Scholar
• Jobbagy M, Regazzoni AE. Dissolution of nano-size Mg-Al-Cl hydrotalcite in aqueous media. Appl Clay Sci 2011;51:366-9
   Web of Science ®Google Scholar
• Del Arco M, Cebadera E, Gutiérrez S, Mg-Al layered double hydroxides with intercalated indomethacin: synthesis, characterization, and pharmacological study. J Pharm Sci 2004;93:1649-58
   PubMed Web of Science ®Google Scholar
• del Arco M, Fernández A, Martín C, Solubility and release of fenamates intercalated in layered double hydroxydes. Clay Miner 2008;43:255-65
   Web of Science ®Google Scholar
• Davis SS. Formulation strategies for absorption windows. Drug Discov Today 2005;10:249-57
   PubMed Web of Science ®Google Scholar
• Granero GE, Longhi MR, Mora MJ, Biowaiver monographs for immediate release solid oral dosage forms: furosemide. J Pharm Sci 2010;99:2544-56
   PubMed Web of Science ®Google Scholar
• Brouwers J, Brewster ME, Augustijns PJ. Supersaturating drug delivery systems: the answer to solubility-limited oral bioavailability? Pharm Sci 2009;98:2549-72
   PubMed Web of Science ®Google Scholar
• Ambrogi V, Perioli L, Pagano C, Use of SBA-15 for furosemide oral delivery enhancement. Eur J Pharm Sci 2012;46:43-8
   PubMed Web of Science ®Google Scholar